BioNTech

Moderna's mRNA-4359 vaccine, designed to activate the immune system against cancer cells, shows promising early results in a phase-one trial with 19 advanced solid tumour patients, with 8 showing no tumour growth and no new tumours. The vaccine is well tolerated without serious adverse effects, and the study now focuses on melanoma and non-small-cell lung cancer patients.

Moderna's mRNA-4359 vaccine, targeting advanced melanoma and solid tumours, shows potential in early trials, with 8 out of 16 patients experiencing no tumour growth. The treatment, using mRNA tech similar to COVID-19 vaccines, primes the immune system to recognize and fight cancer cells, with no serious side effects reported. The results, to be presented at a European oncology conference, mark an important step towards a new cancer treatment.

Moderna’s mRNA cancer vaccine for solid tumours shows early immune response in Phase I/II trial, with 8/16 patients not seeing tumour growth. The vaccine targets PD-L1 and IDO1 proteins, aiming to activate immune cells against cancer. Moderna plans to present interim data at the European Society of Medical Oncology meeting on 14 September.

GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.

CD137 antibodies show promise in cancer immunotherapy by stimulating T cells, with no licensed drugs yet but over 80 in clinical trials, mainly in phase 2. Major companies like BioNTech and Genmab are developing these therapies, which could enhance existing treatments and expand to other diseases. The market potential is significant, with challenges in dosing and resistance needing resolution.

Ryvu Therapeutics reported H1 2024 operating revenues of USD 12.1 million, up USD 4.2 million from H1 2023. As of September 5, 2024, Ryvu's cash position was USD 65.3 million, providing a runway through Q1 2026. The company received the final EUR 6 million tranche from the European Investment Bank and advanced its PRMT5 inhibitor RVU305 for preclinical development, targeting IND/CTA filing in H2 2025. Ryvu is progressing with RVU120 Phase II studies and expects initial data updates at ASH 2024.

GSK discontinues early-stage herpes simplex virus vaccine development after failing TH HSV REC-003 proof-of-concept study. No safety concerns were found, and GSK will continue to collect data for future research. Moderna and BioNTech are advancing their own HSV vaccines.

DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.

CoherentMI's report on the RNA Therapeutics Market projects it to grow from US$2.5M in 2024 to US$948M by 2031, at a CAGR of 68%. The market leverages RNA interference and antisense technologies for gene expression modulation, targeting hereditary disorders, cancer, and infectious diseases. Key players include Alphavax, Arcturus Therapeutics, Atyr Pharma, and Gritstone Bio. The market is driven by increasing R&D investments and demand for precision medicine.

The Basel Area is a leading European hub for life sciences and biotech, attracting major companies like Roche and Novartis. Its appeal lies in a rich ecosystem of research, talent, and infrastructure, making it a prime location for innovation and growth in the sector.